Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
King of Prussia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silenc
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-16 11:30 AM EDT | Phio Pharmaceuticals Corp.
Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026
Dublin, Ireland--(Newsfile Corp. - March 16, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its participation at NVIDIA GTC 2026, the world’s leading conference for artificial intelligence (AI) and accelerated computing, taking place in San Jose (CA), USA, from March 16 to March 19. At the conference, Cosmo will present a technical session titled “Engineering Medical Grade Platforms for Real Time AI
Soins de santé et hôpitaux, Santé
2026-03-16 2:09 AM EDT | Cosmo Pharmaceuticals N.V.
Healthcare Special Opportunities Fund Announces March 2026 Quarterly Distribution
Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - LDIC Inc. (TSX: MDS.UN) (the "Manager"), the manager of Healthcare Special Opportunities Fund (the "Fund"), a closed-end investment fund, today announces the quarterly distribution of CDN$0.06161 per Class A unit and US$0.05573 per Class U unit. The distribution will be paid on or before April 10, 2026, to unitholders of record on March 31, 2026. For further information please conta
Services bancaires / financiers, Soins de santé et hôpitaux
2026-03-13 11:01 AM EDT | Healthcare Special Opportunities Fund
HEALWELL AI Reaches 47 Peer-Reviewed Publications, Strengthening Its Scientific Moat for AI-Powered Real-World Clinical Evidence Generation
HEALWELL achieves its 47th total peer-reviewed publication validating its DARWEN™ AI across multiple disease areas and diverse patient populations. HEALWELL presented new scientific validation of DARWEN™ AI at the European Crohn's and Colitis Organisation (ECCO) meeting, with findings published in the Journal of Crohn's and Colitis(1). The study conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrated how A
Technologies, Soins de santé et hôpitaux
2026-03-12 3:15 AM EDT | HEALWELL AI
Bachem Reports Strong Sales Growth and Sustained High Profitability
Bubendorf, Switzerland--(Newsfile Corp. - March 12, 2026) - Ad hoc announcement pursuant to Art. 53 LR Bachem Reports Strong Sales Growth and Sustained High Profitability Group sales increase to CHF 695.1 million in 2025 (+14.8%, in local currencies +19.2%). EBITDA increases to CHF 214.7 million (+21.8%, in local currencies +32.6%). EBITDA margin lies at 30.9%. Adjusted for one-time effects of CHF 16.1 milli
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-03-12 1:59 AM EDT | Bachem Holding AG
Cosmo Presents Agenda for AGM 2026
Dublin, Ireland--(Newsfile Corp. - March 12, 2026) - Cosmo Pharmaceuticals N.V. (“Cosmo”) is pleased to announce the convening of its upcoming Ordinary Annual General Meeting of Shareholders (AGM) to be held on 10 April 2026 in Amsterdam. The agenda includes, among others, the following discussion and voting items: Report of the Board of Directors on the business year 2025 and the ESG achievements Appropri
Soins de santé et hôpitaux, Santé
2026-03-12 1:58 AM EDT | Cosmo Pharmaceuticals N.V.
Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - March 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced completed enrollment of its pivotal clinical trial for the investigational fully implanted Acclaim® cochlear implant. With the successful implantation of the 56th and final patient, Envoy Medical is the first cochlear implant company to achieve full enro
Biotechnologies, Soins de santé et hôpitaux
2026-03-11 8:00 AM EDT | Envoy Medical, Inc.
Theralase(R) Closes $1.1 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-03-10 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
King of Prussia, Pennsylvania--(Newsfile Corp. - March 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-10 7:00 AM EDT | Phio Pharmaceuticals Corp.
Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies
Orlando, Florida--(Newsfile Corp. - March 9, 2026) - Adia Nutrition's (OTCQB: ADIA) subsidiary, Adia Med, has launched a complete digital refresh of its online presence. Through a strategic partnership with ZenChange Marketing, Adia Med has relaunched its website with a modern, streamlined design focused on transparency, accessibility, and clear information about its investigational studies. The update makes it easier for families, researchers, and healthcare professionals to explore the orga
Soins de santé et hôpitaux, Santé
2026-03-09 9:38 AM EDT | Adia Nutrition Inc.
Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to present its latest preclinical data demonstrating that X-Ray-activated Rutherrin® is effective in th
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-03-09 7:00 AM EDT | Theralase Technologies Inc.
HEALWELL AI to Announce Fourth Quarter and Year End 2025 Financial Results on March 19, 2026
Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce the Company will release its Fiscal Fourth Quarter and Year End 2025 financial results for
Technologies, Soins de santé et hôpitaux
2026-03-09 3:15 AM EDT | HEALWELL AI
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Ad hoc announcement pursuant to Art. 53 LR Full Year 2025 revenue of €104.2 million, in line with guidance, with 85% recurring revenues Recurring revenues of €88.1 million, +15% year-over-year, reflecting structural business transformation EBITDA of €9.5 million, exceeding the upper end of guidance
Soins de santé et hôpitaux, Santé
2026-03-09 2:00 AM EDT | Cosmo Pharmaceuticals N.V.
TGI Solar Power Group (TSPG) Signs LOI to Acquire XGC Corp to Build National Carbon Registries Under Paris Agreement Article 6.4
Florida and Toronto, Ontario--(Newsfile Corp. - March 6, 2026) - TGI Solar Power Group, Inc. (OTC: TSPG), a diversified sustainable infrastructure and clean-energy technology holding company, today announced it has signed a Letter of Intent (LOI) to acquire XGC Corp, an Ontario-based developer of sovereign-grade carbon registry infrastructure powered by artificial intelligence, blockchain technology, and enterprise financial systems. The proposed transaction
Technologies, Soins de santé et hôpitaux
2026-03-06 5:30 PM EST | XGC Software Inc.
Apolo V Acquisition Corp. Announces Shareholder Approvals
Toronto, Ontario--(Newsfile Corp. - March 6, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo" or the "Company"), a "capital pool company" pursuant to the policies of the TSX Venture Exchange (the "TSXV"), is pleased to announce the voting results from its Special Meeting of Shareholders (the "Apolo Meeting") held on Thursday, March 5, 2026 in connection with its previously announced proposed qualifying transaction (the "Qualifying Transaction"
Soins de santé et hôpitaux, Santé
2026-03-06 9:08 AM EST | TelyRx
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeuti
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 4:05 PM EST | Phio Pharmaceuticals Corp.
AliMed Launches New Line of Lightweight Hybrid Gel-Foam Positioners Aimed at Improving Safety for Patients and Staff
Dedham, Massachusetts--(Newsfile Corp. - March 5, 2026) - AliMed, LLC, a Massachusetts-based medical device manufacturer and distributor, is introducing its own line of innovative hybrid gel-foam positioners, expanding its broad portfolio of patient positioners. This unique design delivers the benefits of all-gel positioners with up to 50% reduction in weight. These new positioners are being sold under the name AliBlue™ L
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 10:00 AM EST | AliMed, LLC
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - March 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-03-05 7:00 AM EST | Phio Pharmaceuticals Corp.
HEALWELL AI Announces Multi-Million Dollar U.S. Health Information Exchange Contract and AI-Driven Pipeline Momentum
HEALWELL has signed a multi-million dollar, multi-year U.S.-based Health Information Exchange (HIE) software contract following a competitive procurement process. Strong momentum in all parts of the software pipeline including renewals, extensions, short listing and intent to award have advanced across core markets, reinforcing recurring data infrastructure revenue. Increasing participation in coordinated, enterprise-scale RFP bids leveraging Orion Health's global footpri
Technologies, Soins de santé et hôpitaux
2026-03-05 3:15 AM EST | HEALWELL AI
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Dublin, Ireland--(Newsfile Corp. - March 5, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced a strategic Research and Development Agreement with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an artificial intelligence (AI)-based computer-aided detection (CADe) system for the identification of early neoplasia in Barrett’s esophagus. The collaboration represents an important step in ex
Soins de santé et hôpitaux, Santé
2026-03-05 1:00 AM EST | Cosmo Pharmaceuticals N.V.